Do you avoid immunotherapy in patients with Stage IV NSCLC with atypical EGFR mutations such as G719S or S768I?  

This is a difficult situation, but typically I would try to treat patients with an EGFR TKI (ideally in the context of a clinical trial) or with afatinib. Pooled data from the LUX-Lung studies [Yang et al., PMID 26051236] demonstrated an ORR of 71%, PFS 10.7 months, and OS of 19.4 months for Group 1...